This Swedish nationwide longitudinal research included 192 sufferers who underwent esophagectomy for most cancers. The publicity was dispositional optimism measured by the Life Orientation Check-Revised (LOT-R) at 1 yr post-surgery. Sufferers have been categorized into 4 subgroups (very low, reasonably low, reasonably excessive, and really excessive dispositional optimism) primarily based on the quartile of the LOT-R sum rating. The result was HRQL assessed by the European Group for Analysis and Therapy of Most cancers High quality of Life Questionnaire-Core 30 and High quality of Life Questionnaire-Esophago-Gastric module 25 at 1, 1.5, and a couple of years post-surgery.
Linear mixed-effects fashions, adjusted for potential confounders, have been used to look at the imply rating distinction (MSD) with 95% confidence interval of HRQL among the many 4 affected person subgroups. Sufferers with very excessive dispositional optimism reported clinically relevantly higher world high quality of life, emotional perform, and social perform (MSD vary 10-16) and fewer extreme signs in ache, dyspnea, diarrhea, consuming problem, anxiousness, dry mouth, bother with style, fear about weight reduction, and self-doubt about physique picture (MSD vary – 9 to – 22) than sufferers with decrease dispositional optimism.
Sufferers with reasonably excessive dispositional optimism reported clinically and statistically considerably higher world high quality of life (MSD 10) and fewer extreme diarrhea (MSD – 9) than sufferers with decrease dispositional optimism. Adjusted MSDs have been fixed over the three time factors in all features aside from consuming problem. Subsequently, the DF-based SA successfully solves the issue of fabric shedding and growing older, thus enhancing the soundness and injury threshold of the fiber laser.
COVID-19: unbalanced administration of occupational risks-case of the evaluation of the chemical threat associated to the usage of disinfectants within the dairy business in Morocco
Moroccan employers have a robust duty for the security and well being of their staff within the office and for shielding them from the chance of COVID-19 and any occupational hazards, as required by Moroccan legislation. As a consequence, industries, together with the agri-food sector, have put in place preventive measures to cope with this pandemic on a number of fronts, together with the usage of hydroalcoholic merchandise and bleach for private and floor disinfection.
These disinfection actions might remove or scale back the chance of coronavirus an infection, however the elevated use of those merchandise by staff may result in critical well being issues and improve the occupational chemical threat within the occasion of uncontrolled publicity. With the intention to analyze this threat within the dairy business in Morocco, we now have launched a qualitative and quantitative research to establish and assess the severity of chemical threat to which its staff are uncovered.
This includes an evaluation of the security information sheets [MSDS] of the disinfectants used and a well being and security survey of the customers of those merchandise, significantly for hand disinfection. This evaluation confirmed that this chemical threat is omnipresent and prevention measures are partially adopted. Certainly, the strengthening of well being security measures to fight COVID-19 has considerably elevated this threat, leading to a outstanding imbalance within the evaluation and administration of occupational dangers on this business.
That is the usage of the Danger Evaluation-Important Management Factors (HACCP)-Instrument for a First Danger Evaluation by Exercise Evaluation (OPERA) method, which we developed and proposed in a earlier research, for a simplified administration of chemical threat within the meals business, particularly in small- and medium-sized enterprises. These outcomes have led us to suggest corrective and preventive measures towards this threat to events and to undertake an built-in administration of meals and occupational well being dangers in a single system.
Monitoring-based deep studying methodology for temporomandibular joint segmentation
The form, measurement, and floor info regarding the glenoid fossae and condyles in temporomandibular joints (TMJ) are important for diagnosing and treating. Sufferers with TMJ illness usually have floor abrasion which can trigger fuzzy edges in computed tomography (CT) imaging, particularly for low-dose CT, making TMJ segmentation harder. On this paper, an computerized segmentation algorithm primarily based on deep studying and post-processing was launched.
First, U-Internet was used to divide photos into three classes: glenoid fossae, condyles, and background. For structural fractures in these divided photos, the inner pressure constraint of a snake mannequin was used to replenish the integrity of the fracture boundary in a post-processing operation, and the preliminary boundary of the snake was obtained primarily based on the idea of the monitoring idea. A complete of 206 instances of low-dose CT have been used to confirm the effectiveness of the algorithm, and such indicators because the Cube coefficient (DC) and imply floor distance (MSD) have been used to judge the settlement between experimental outcomes and the gold normal.
E. coli gyrase ATPase assay Kit Plus (enzyme included) |
T2A-100KE |
ProFoldin |
100 assays |
EUR 444.91 |
Description: This product includes the reaction buffer, DNA, E. coli gyrase, ATP and the phosphate detection reagent for 100 assays of DNA supercoiling reactions in a 384-well assay format. |
P. aeruginosa Gyrase ATPase assay Kit Plus (enzyme included) |
T2A-100KP |
ProFoldin |
100 assays |
EUR 444.91 |
Description: This product includes the reaction buffer, DNA, P. aeruginosa gyrase, ATP and the phosphate detection reagent for 100 assays of DNA supercoiling reactions in a 384-well assay format. |
S. aureus gyrase ATPase assay Kit Plus (enzyme included) |
T2A-100KS |
ProFoldin |
100 assays |
EUR 423.72 |
Description: This product includes the reaction buffer, DNA, S. aureus gyrase, ATP and the phosphate detection reagent for 100 assays of DNA supercoiling reactions in a 384-well assay format. |
CD28 antigen (CD28) polyclonal antibody |
ABP-PAB-10144 |
Allele Biotech |
100 ug |
Ask for price |
|
pCDH-CuO-MCS-T2A-GFP co-inducible T2A lentivector |
QM521A-1 |
SBI |
10 ug |
EUR 814.8 |
|
pCDH-CuO-MCS-T2A-RFP co-inducible T2A lentivector |
QM522A-1 |
SBI |
10 ug |
EUR 814.8 |
|
CD28 Peptide |
42-404P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) CD28 Peptide |
Cd28 Peptide |
42-448P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) Cd28 Peptide |
CD28 antibody |
70R-49503 |
Fitzgerald |
100 ul |
EUR 344.4 |
Description: Purified Polyclonal CD28 antibody |
CD28 Antibody |
46435-100ul |
SAB |
100ul |
EUR 302.4 |
CD28 antibody |
10R-6375 |
Fitzgerald |
100 ug |
EUR 230.4 |
Description: Syrian Hamster monoclonal CD28 antibody |
CD28 antibody |
10R-6376 |
Fitzgerald |
100 ug |
EUR 230.4 |
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
10R-CD28bHU |
Fitzgerald |
100 ul |
EUR 560.4 |
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
10R-CD28dCKp |
Fitzgerald |
500 ug |
EUR 483.6 |
Description: Mouse monoclonal CD28 antibody |
CD28 antibody |
10R-CD28dMS |
Fitzgerald |
500 ug |
EUR 444 |
Description: Hamster monoclonal CD28 antibody |
CD28 antibody |
10R-CD28eMS |
Fitzgerald |
500 ug |
EUR 444 |
Description: Hamster monoclonal CD28 antibody |
CD28 siRNA |
20-abx900903 |
Abbexa |
|
|
|
CD28 siRNA |
20-abx910984 |
Abbexa |
|
|
|
CD28 siRNA |
20-abx910985 |
Abbexa |
|
|
|
CD28 Antibody |
8683-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: N/A |
CD28 Antibody |
8683-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: N/A |
CD28 Peptide |
8683P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: CD28 peptide |
CD28 antibody |
70R-CR045 |
Fitzgerald |
100 ug |
EUR 360 |
Description: Affinity purified Rabbit polyclonal CD28 antibody |
CD28 antibody |
70R-9669 |
Fitzgerald |
50 ug |
EUR 560.4 |
Description: Affinity purified rabbit polyclonal CD28 antibody |
CD28 Antibody |
1-CSB-PA005199 |
Cusabio |
|
|
|
Description: A polyclonal antibody against CD28. Recognizes CD28 from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000 |
CD28/TP44 |
E21-D81 |
EnoGene |
10ug |
EUR 411.6 |
anti-CD28 |
YF-PA10780 |
Abfrontier |
50 ug |
EUR 435.6 |
Description: Mouse polyclonal to CD28 |
Recombinant Cynomolgus CD28 molecule/CD28(C-Fc) |
CB24-10ug |
Novoprotein |
10ug |
EUR 120 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Cynomolgus CD28 molecule/CD28(C-Fc) |
CB24-1mg |
Novoprotein |
1mg |
EUR 1338 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Cynomolgus CD28 molecule/CD28(C-Fc) |
CB24-500ug |
Novoprotein |
500ug |
EUR 936 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
Recombinant Cynomolgus CD28 molecule/CD28(C-Fc) |
CB24-50ug |
Novoprotein |
50ug |
EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS,pH7.4. |
T-cell-specific surface glycoprotein CD28/CD28 |
E21-I67 |
EnoGene |
10ug |
EUR 411.6 |
T2A-GFP Co-Expression HR Targeting Vector [T2A-GFP-pA-loxP-EF1?-RFP-T2A-Puro-pA-LoxP-MCS] |
HR130PA-1 |
SBI |
10 ug |
EUR 1227.6 |
|
CD28 antibody (FITC) |
61R-1069 |
Fitzgerald |
50 ug |
EUR 217.2 |
Description: Mouse monoclonal CD28 antibody (FITC) |
CD28 antibody (PE) |
61R-1231 |
Fitzgerald |
200 ug |
EUR 573.6 |
Description: Mouse monoclonal CD28 antibody (PE) |
CD28 antibody (PE) |
61R-1232 |
Fitzgerald |
100 ug |
EUR 418.8 |
Description: Syrian Hamster monoclonal CD28 antibody (PE) |
CD28 antibody (biotin) |
61R-1489 |
Fitzgerald |
100 ug |
EUR 379.2 |
Description: Syrian Hamster monoclonal CD28 antibody (biotin) |
CD28 antibody (biotin) |
61R-1490 |
Fitzgerald |
100 ug |
EUR 379.2 |
Description: Mouse monoclonal CD28 antibody (biotin) |
CD28 antibody (allophycocyanin) |
61R-1717 |
Fitzgerald |
100 ug |
EUR 573.6 |
Description: Syrian Hamster monoclonal CD28 antibody (allophycocyanin) |
CD28 antibody (biotin) |
61R-CD28dCKBT |
Fitzgerald |
500 ug |
EUR 548.4 |
Description: Mouse monoclonal CD28 antibody (biotin) |
CD28 antibody (FITC) |
61R-CD28dCKFT |
Fitzgerald |
500 ug |
EUR 678 |
Description: Mouse monoclonal CD28 antibody (FITC) |
CD28 antibody (PE) |
61R-CD28dCKPE |
Fitzgerald |
100 ug |
EUR 418.8 |
Description: Mouse monoclonal CD28 antibody (PE) |
CD28 antibody (Allophycocyanin) |
61R-CD28dMSAPC |
Fitzgerald |
100 ug |
EUR 548.4 |
Description: Hamster monoclonal CD28 antibody (Allophycocyanin) |
CD28 antibody (biotin) |
61R-CD28dMSBT |
Fitzgerald |
500 ug |
EUR 522 |
Description: Hamster monoclonal CD28 antibody (biotin) |
CD28 antibody (FITC) |
61R-CD28dMSFT |
Fitzgerald |
500 ug |
EUR 522 |
Description: Hamster monoclonal CD28 antibody (FITC) |
CD28 antibody (PE) |
61R-CD28dMSPE |
Fitzgerald |
200 ug |
EUR 535.2 |
Description: Hamster monoclonal CD28 antibody (PE) |
CD28 antibody (Allophycocyanin) |
61R-CD28eMSAPC |
Fitzgerald |
100 ug |
EUR 548.4 |
Description: Hamster monoclonal CD28 antibody (Allophycocyanin) |
CD28 antibody (biotin) |
61R-CD28eMSBT |
Fitzgerald |
500 ug |
EUR 522 |
Description: Hamster monoclonal CD28 antibody (biotin) |
CD28 antibody (FITC) |
61R-CD28eMSFT |
Fitzgerald |
500 ug |
EUR 522 |
Description: Hamster monoclonal CD28 antibody (FITC) |
CD28 antibody (PE) |
61R-CD28eMSPE |
Fitzgerald |
200 ug |
EUR 535.2 |
Description: Hamster monoclonal CD28 antibody (PE) |
CD28 Polyclonal Antibody |
A1076-100 |
Biovision |
|
EUR 483.6 |
CD28 antibody (Tyr218) |
70R-33478 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal CD28 antibody (Tyr218) |
CD28 Polyclonal Antibody |
41651-100ul |
SAB |
100ul |
EUR 302.4 |
CD28 Polyclonal Antibody |
41651-50ul |
SAB |
50ul |
EUR 224.4 |
CD28 Blocking Peptide |
33R-9340 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CD28 antibody, catalog no. 70R-9669 |
CD28 Recombinant Protein |
90-392 |
ProSci |
200 ug |
EUR 714.3 |
Description: CD28 and CTLA-4 together with their ligands, CD80 (B7-1) and CD86 (B7-2), constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD28 and CTLA-4 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD28 and CTLA-4 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD28 and CTLA-4 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2 and mouse chromosome 1. Mouse CD28 is expressed constitutively on virtually 100% of mouse T cells and on developing thymocytes. Cell surface expression of mouse CD28 is downregulated upon ligation of CD28 in the presence of PMA or PHA. In contrast, CTLA-4 is not expressed constitutively but is upregulated rapidly following T cell activation and CD28 ligation. Cell surface expression of mouse CTLA-4 peaks approx.y 48 hours after activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28. CD28/B7 interaction has been shown to prevent apoptosis of activated T cells via the upregulation of bcl-XL. CD28 ligation has also been shown to regulate Th1/Th2 differentiation. |
CD28 Recombinant Protein |
90-393 |
ProSci |
200 ug |
EUR 714.3 |
Description: CD28 and CTLA-4 together with their ligands, CD80 (B7-1) and CD86 (B7-2), constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD28 and CTLA-4 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD28 and CTLA-4 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD28 and CTLA-4 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. The genes encoding these two molecules are closely linked on human chromosome 2 and mouse chromosome 1. Mouse CD28 is expressed constitutively on virtually 100% of mouse T cells and on developing thymocytes. Cell surface expression of mouse CD28 is downregulated upon ligation of CD28 in the presence of PMA or PHA. In contrast, CTLA-4 is not expressed constitutively but is upregulated rapidly following T cell activation and CD28 ligation. Cell surface expression of mouse CTLA-4 peaks approx.y 48 hours after activation. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28. CD28/B7 interaction has been shown to prevent apoptosis of activated T cells via the upregulation of bcl-XL. CD28 ligation has also been shown to regulate Th1/Th2 differentiation. |
CD28 Recombinant Protein |
91-952 |
ProSci |
0.05 mg |
EUR 374.1 |
Description: T-cell-specific surface glycoprotein CD28(CD28) is a single-pass typeI membrane protein which contains one Ig-likeV-type (immunoglobulin-like) domain. It belongs to the immunoglobulin(Ig) superfamily. CD28 is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation.CD28 co-stimulation is necessary for CD4 positive T-cell proliferation and survival, interleukin-2 production, and T-helper type-2 development. Human post-thymic regulatory T cells require CD28 co-stimulation to expand and maintain potent suppressive function in vivo. Apoptosis plays a key role in the age-related decline of CD28 expression and in immunosenescence. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells. |
CD28 Recombinant Protein |
92-372 |
ProSci |
0.05 mg |
EUR 374.1 |
Description: T-cell-specific surface glycoprotein CD28, contains an Ig-like V-type domain. CD28 is one of the proteins expressed on T cells that provide co-stimulatory signals, which are required for their activation. It is the receptor for CD80 and CD86. When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells. It involved in T-cell activation, the induction of cell proliferation and cytokine production and promotion of T-cell survival. |
Hamster CD28 Antibody |
abx139999-01mg |
Abbexa |
0.1 mg |
EUR 343.2 |
|
CD28 Polyclonal Antibody |
ABP52975-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
Description: A polyclonal antibody for detection of CD28 from Human. This CD28 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD28 |
CD28 Polyclonal Antibody |
ABP52975-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
Description: A polyclonal antibody for detection of CD28 from Human. This CD28 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD28 |
CD28 Polyclonal Antibody |
ABP52975-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
Description: A polyclonal antibody for detection of CD28 from Human. This CD28 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human CD28 |
CD28 (pT218) Antibody |
20-abx009853 |
Abbexa |
-
EUR 376.80
-
EUR 560.40
-
EUR 243.60
|
|
|
CD28 Rabbit pAb |
A17447-100ul |
Abclonal |
100 ul |
EUR 369.6 |
CD28 Rabbit pAb |
A17447-200ul |
Abclonal |
200 ul |
EUR 550.8 |
CD28 Rabbit pAb |
A17447-20ul |
Abclonal |
20 ul |
EUR 219.6 |
CD28 Rabbit pAb |
A17447-50ul |
Abclonal |
50 ul |
EUR 267.6 |
CD28 Rabbit mAb |
A20346 |
Abclonal |
20 μL |
EUR 18 |
CD28 Recombinant Protein |
96-979 |
ProSci |
0.1 mg |
EUR 651.3 |
Description: T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells. |
CD28 Recombinant Protein |
96-980 |
ProSci |
0.1 mg |
EUR 556.8 |
Description: T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells. |
CD28(204.12) Antibody |
BNC040164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF405S conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC040164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF405S conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC040384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF405S conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC040384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF405S conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC050164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF405M conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC050164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF405M conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC050384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF405M conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC050384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF405M conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCAP0164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCAP0164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCAP0384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCAP0384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCB0164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), Biotin conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCB0164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), Biotin conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCB0384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), Biotin conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCB0384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), Biotin conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCP0164-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(204.12), PerCP conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCP0384-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(CB28), PerCP conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCR0164-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(204.12), RPE conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCR0384-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(CB28), RPE conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC940164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF594 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC940164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF594 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC940384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF594 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC940384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF594 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCA0164-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(204.12), APC conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCA0384-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against CD28(CB28), APC conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC810164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF680R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC810164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF680R conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC810384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF680R conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC810384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF680R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNUB0164-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD28(204.12), Concentration: 0.2mg/mL |
CD28(204.12) Antibody |
BNUB0164-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD28(204.12), Concentration: 0.2mg/mL |
CD28(CB28) Antibody |
BNUB0384-100 |
Biotium |
100uL |
EUR 250.8 |
Description: Primary antibody against CD28(CB28), Concentration: 0.2mg/mL |
CD28(CB28) Antibody |
BNUB0384-500 |
Biotium |
500uL |
EUR 549.6 |
Description: Primary antibody against CD28(CB28), Concentration: 0.2mg/mL |
CD28(204.12) Antibody |
BNCH0164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNCH0164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCH0384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNCH0384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC880164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF488A conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC880164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF488A conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC880384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF488A conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC880384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF488A conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC680164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF568 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC680164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF568 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC680384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF568 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC680384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF568 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC470164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF647 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC470164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF647 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC470384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF647 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC470384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF647 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC400384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF640R conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC400384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF640R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC430164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF543 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC430164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF543 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC430384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF543 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC430384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF543 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC610164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF660R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC610164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF660R conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC610384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF660R conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC610384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF660R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC800164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF680 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC800164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF680 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC800384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF680 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC800384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF680 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC400164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF640R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC400164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF640R conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC550164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF555 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC550164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF555 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC550384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF555 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC550384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF555 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC700164-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(204.12), CF770 conjugate, Concentration: 0.1mg/mL |
CD28(204.12) Antibody |
BNC700164-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(204.12), CF770 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC700384-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against CD28(CB28), CF770 conjugate, Concentration: 0.1mg/mL |
CD28(CB28) Antibody |
BNC700384-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against CD28(CB28), CF770 conjugate, Concentration: 0.1mg/mL |
Utility of the SA in erbium-doped fiber laser and steady passive Q-switched operation with a most pulse power of 430.47 nJ is realized. By adjusting the polarization state and pump energy, high-power mode-locked pulses are generated with a pulse period and output energy of 199 fs and 54.13 mW, respectively. Additional, bound-state soliton pulses are obtained with a pulse width of 312 fs and soliton interval of 1.26 ps for the primary time primarily based on MXene supplies. Furthermore, by utility of the SA in ytterbium-doped fiber lasers, a steady dissipative soliton mode-locked pulse is obtained with a pulse width of 23 ps. These outcomes point out that the DF-based buried Mo2C as a novel SA offers a dependable methodology for all-fiber and multifunctional high-power ultrafast laser.